Pulmonary Fibrosis and Telomerase Dysfunction
Pulmonary Fibrosis and Telomerase Dysfunction
批准号:
9100521
负责人:
Christine Kim Garcia
金额:
$40.16万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-03-06 至 2019-04-30
关键词:
AddressAgeAgingApplications GrantsArchitectureBiologicalCandidate Disease GeneCell LineCessation of lifeChromosomesCicatrixCodeComputer SimulationDataData SetDefectDiagnosisDiseaseEnvironmental Risk FactorEnzymesEpithelial CellsFamilyFemaleFibrosisFrequenciesFunctional ImagingFunctional disorderGasesGene FrequencyGene SilencingGenesGeneticGenomic SegmentGoalsHamman-Rich syndromeHealthHomeostasisHumanIndividualInheritedInterstitial Lung DiseasesInvestigationLeadLengthLeukocytesLifeLife ExpectancyLinkLungLung diseasesMeasuresMethodsMolecularMutationNucleotidesPathogenesisPathway interactionsPatientsPhenotypePopulationPositioning AttributeProteinsPulmonary FibrosisRNAResearchRibonucleoproteinsRoleSequence AnalysisSkin TissueTelomeraseTelomerase RNA ComponentTelomere MaintenanceTelomere ShorteningTherapeutic InterventionTissuesVariantbasecell growth regulationcirculating biomarkersclinical phenotypecohortdisorder subtypeexome sequencinggene discoverygenetic linkage analysisgenetic varianthuman diseaseinsightkindredloss of function mutationmalemutantmutational statusnext generationnext generation sequencingnoveloutcome forecastoverexpressionperipheral bloodprogramsprotein functionprototyperare variantresearch clinical testingsegregationtelomeretooltranscriptomewhole genome
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Pulmonary fibrosis characterizes a heterogeneous group of lung disorders with irreversible destruction of lung architecture and disruption of gas exchange. The prototype of these diseases, idiopathic pulmonary fibrosis (IPF), has a short median life expectancy from diagnosis to death. Mutations in the genes encoding the protein component (TERT) or RNA component (TERC) of telomerase, a ribonucleoprotein enzyme that catalyzes the addition of hexameric nucleotide repeats to the ends of linear chromosomes, cause disease in a subset of kindreds with familial pulmonary fibrosis. An equal number of families has evidence of telomerase dysfunction, with very short peripheral blood telomere lengths, but no coding mutations in the telomerase genes. Our hypothesis is that short telomere lengths, caused by mutations in genes other than TERT or TERC, represent an important mechanism underlying IPF. In this grant application we merge traditional clinical phenotyping and linkage methods with next generation exome sequencing to provide new insights into IPF genetics. First, we will characterize the clinical phenotype associated with very short telomere lengths in rare kindreds that demonstrate autosomal dominant co-segregation of pulmonary fibrosis and short telomere lengths. Since extreme phenotypes represent a powerful tool for gene discovery, we will use clinical evaluations and analyses of tissue telomerase expression, lung transcriptome signatures and circulating biomarkers to characterize the short telomere IPF phenotype. Second, we will use next generation exome sequencing to identify rare candidate variants in the discovery cohort of kindreds without mutations in known familial pulmonary fibrosis genes. The datasets will be filtered and prioritized by four independent methods: (1) by genomic regions co- segregating with the phenotypes of lung fibrosis and/or short telomere length, (2) by allele frequency, (3) by predicted deleterious effects on protein function and (4) b gene-based frequencies and their biological roles in telomere and fibrosis pathways. The final aim will validate candidate variants by co-segregation in the kindreds they were discovered, by association studies and by investigations of protein variant function. These studies have the potential to break new grounds by determining how telomere shortening leads to lung fibrosis. Our multi-pronged approach offers the promise of new targets for therapeutic intervention and will lead to better understanding of the pathogenesis of progressive lung fibrosis due to telomerase dysfunction.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Mutant Surfactant - Induced TGF-beta Secretion in Lung Fibrosis
-
批准号:8613014
-
项目类别:
-
资助金额:$51.36万
-
财政年份:2014
-
负责人:Christine Kim Garcia
-
依托单位:
Mutant Surfactant - Induced TGF-beta Secretion in Lung Fibrosis
-
批准号:9199592
-
项目类别:
-
资助金额:$45.95万
-
财政年份:2014
-
负责人:Christine Kim Garcia
-
依托单位:
Subclinical Interstitial Lung Disease in MESA and FAR-ILD
-
批准号:9926302
-
项目类别:
-
资助金额:$77.69万
-
财政年份:2011
-
负责人:Christine Kim Garcia
-
依托单位:
Pulmonary Fibrosis and Telomerase Dysfunction
-
批准号:10646270
-
项目类别:
-
资助金额:$70.3万
-
财政年份:2009
-
负责人:Christine Kim Garcia
-
依托单位:
Pulmonary Fibrosis and Telomerase Dysfunction
-
批准号:7822299
-
项目类别:
-
资助金额:$1.57万
-
财政年份:2009
-
负责人:Christine Kim Garcia
-
依托单位:
Pulmonary Fibrosis and Telomerase Dysfunction
-
批准号:7591551
-
项目类别:
-
资助金额:$38.13万
-
财政年份:2009
-
负责人:Christine Kim Garcia
-
依托单位:
Pulmonary Fibrosis and Telomerase Dysfunction
-
批准号:10435541
-
项目类别:
-
资助金额:$71.88万
-
财政年份:2009
-
负责人:Christine Kim Garcia
-
依托单位:
Pulmonary Fibrosis and Telomerase Dysfunction
-
批准号:8035331
-
项目类别:
-
资助金额:$44.85万
-
财政年份:2009
-
负责人:Christine Kim Garcia
-
依托单位:
Pulmonary Fibrosis and Telomerase Dysfunction
-
批准号:8980114
-
项目类别:
-
资助金额:$43.77万
-
财政年份:2009
-
负责人:Christine Kim Garcia
-
依托单位:
Pulmonary Fibrosis and Telomerase Dysfunction
-
批准号:8011136
-
项目类别:
-
资助金额:$0.96万
-
财政年份:2009
-
负责人:Christine Kim Garcia
-
依托单位:
Pulmonary Fibrosis and Telomerase Dysfunction
-
批准号:8434137
-
项目类别:
-
资助金额:$41.45万
-
财政年份:2009
-
负责人:Christine Kim Garcia
-
依托单位:
Pulmonary Fibrosis and Telomerase Dysfunction
-
批准号:7842028
-
项目类别:
-
资助金额:$22.86万
-
财政年份:2009
-
负责人:Christine Kim Garcia
-
依托单位:
Pulmonary Fibrosis and Telomerase Dysfunction
-
批准号:10299279
-
项目类别:
-
资助金额:$73.94万
-
财政年份:2009
-
负责人:Christine Kim Garcia
-
依托单位:
Pulmonary Fibrosis and Telomerase Dysfunction
-
批准号:8230642
-
项目类别:
-
资助金额:$44.5万
-
财政年份:2009
-
负责人:Christine Kim Garcia
-
依托单位:
Pulmonary Fibrosis and Telomerase Dysfunction
-
批准号:9262270
-
项目类别:
-
资助金额:$40.18万
-
财政年份:2009
-
负责人:Christine Kim Garcia
-
依托单位:
Pulmonary Fibrosis and Telomerase Dysfunction
-
批准号:7781396
-
项目类别:
-
资助金额:$44.85万
-
财政年份:2009
-
负责人:Christine Kim Garcia
-
依托单位:
CHARACTERIZATION OF FAMILIAL IDIOPATHIC PULMONARY FIBROSIS
-
批准号:7606332
-
项目类别:
-
资助金额:$0.04万
-
财政年份:2007
-
负责人:Christine Kim Garcia
-
依托单位:
CLINICAL CHARACTERIZATION OF FAMILIAL SPONTANEOUS PNEUMOTHORAX
-
批准号:7606331
-
项目类别:
-
资助金额:$0.02万
-
财政年份:2007
-
负责人:Christine Kim Garcia
-
依托单位:
CHARACTERIZATION OF FAMILIAL IDIOPATHIC PULMONARY FIBROSIS
-
批准号:7377636
-
项目类别:
-
资助金额:$4.58万
-
财政年份:2006
-
负责人:Christine Kim Garcia
-
依托单位:
The Molecular Basis of Familial Spontaneous Pneumothorax
-
批准号:7649423
-
项目类别:
-
资助金额:$15.12万
-
财政年份:2005
-
负责人:Christine Kim Garcia
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: